Cubist Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cubist Pharmaceuticals, Inc.
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
The acquisitions of Alexion and Celgene are the latest in a long line of transactions in which big pharma buys big biotech. But these latest two are of biotechs that have disappointed their investors, and there are still some of those left for 2021.
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
- Other Names / Subsidiaries
- Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.